Tirzepatide Improves HRQoL Compared to Insulin Lispro in Poorly Controlled Basal Insulin-treated Adults with Long-standing T2D (SURPASS-6)
Diabetologie und Stoffwechsel · 01.04.2024 · 19 (S 01 S 01) · S74
DOI: 10.1055/s-0044-1785382 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetologie und Stoffwechsel, erschienen am 01.04.2024. Verfasst von Kristina Boye und 7 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref).
Abstract (Originalsprache)
Does tirzepatide (TZP) improve HRQoL compared to insulin lispro (iLispro) in adults with type 2 diabetes (T2D) treated with basal insulin?
Methods
In SURPASS-6, adults with T2D and inadequate glycemic control were randomized (1:1:1:3) to TZP 5, 10, or 15 mg QW, or iLispro TID, as add-on to optimized insulin glargine, with or without metformin, for 52 weeks in this open-label, multicenter, Phase 3b study. HRQoL was measured at baseline and endpoint (Week 52) using the SF-36v2 acute form comprised of 8 domains and 2 component summary scores.
Results
Overall, 1428 participants with mean baseline age 59 y, T2D duration 14 y, HbA1c 8.8% and BMI 33.1 kg/m2 were randomized. At endpoint, TZP-treated participants had statistically significantly improved scores across all SF-36v2 domains and component summaries compared to iLispro-treated participants, with the largest differences observed in the General health (LS mean [SE] change 3.0 [0.31] vs. -0.1 [0.32]) and Vitality (1.5 [0.31] vs. -1.1 [0.32]) domains.
Conclusion
TZP treatment resulted in greater improvements across multiple domains of HRQoL than iLispro in adults with long standing T2D already treated with basal insulin. Publication History Article published online: 18 April 2024 © 2024. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
Zitieren
APA
Boye, K., Sapin, H., Poon, J. L., Landó, L. F., Huh, R., Wang, M., Patel, H., & Scholz, B. (2024). Tirzepatide Improves HRQoL Compared to Insulin Lispro in Poorly Controlled Basal Insulin-treated Adults with Long-standing T2D (SURPASS-6). Diabetologie und Stoffwechsel, 19(S 01 S 01), S74. https://doi.org/10.1055/s-0044-1785382
Vancouver
Boye K, Sapin H, Poon JL, Landó LF, Huh R, Wang M, et al. Tirzepatide Improves HRQoL Compared to Insulin Lispro in Poorly Controlled Basal Insulin-treated Adults with Long-standing T2D (SURPASS-6). Diabetologie und Stoffwechsel. 2024;19(S 01 S 01):S74. doi:10.1055/s-0044-1785382
BibTeX
@article{Boye2024,
author = {Boye, Kristina and Sapin, Helene and Poon, Jiat Ling and Landó, Laura Fernández and Huh, Ruth and Wang, Mianbo and Patel, Hiren and Scholz, Bernd-M.},
title = {Tirzepatide Improves HRQoL Compared to Insulin Lispro in Poorly Controlled Basal Insulin-treated Adults with Long-standing T2D (SURPASS-6)},
journal = {Diabetologie und Stoffwechsel},
year = {2024},
volume = {19},
number = {S 01 S 01},
pages = {S74},
doi = {10.1055/s-0044-1785382}
}
EUVIMED